Подтвердите e-mail

Для публикаций, комментариев, реакций и сообщений подтвердите адрес.

Профиль

Saloni

Профиль Vively

Co-founder & editor, Works in Progress. Writer, Scientific Discovery. Podcaster, Hard Drugs. Advisor, Coefficient Giving. // Previously at Our World in Data. Newsletter: https://scientificdiscovery.dev Podcast: https://harddrugs.worksinprogress.co 🏳️‍🌈

If you wanna catch up on new research in your networks, I recommend this bsky feed! It's great. It shows you posts linking to academic papers - from people you already follow. I've found it very useful so far.

3305

Whooops. I made a mistake while describing the mechanism of immortal time bias in our last episode. Ironically, it was just after I explained how confusing I found many explanations of it, but my own explanation was also confused! 😂🫠

1110

Nice piece by @wilsonmking.bsky.social on a surprisingly unsolved question: Why are Indian kids so short? (Even more than India's development would imply.) It felt a bit voyeuristic to me though, like reading about myself or something.

The Mystery of Short Indian Children – In Developmentevidence and argument for a developing worldindevelopmentmag.com
4256

This is a really beautiful website by @jdworkin.bsky.social on the everyday household items that were once only dreamt about – a music player, nightlight, family photos, clean water, ice, spices, and more. 10/10 would recommend exploring it! ordinaryabundance.com

Ordinary AbundanceA walk through a modern apartment, through the eyes of the people for whom everything in it was new.ordinaryabundance.com
210431

I'm interested in finding and potentially supporting people who are interested in doing long-form writing on the big efforts in global health: Gavi, Global Fund, PEPFAR, etc. If this is you or someone you know, please make yourself known!

58074

I love this clip of @jacobtref.bsky.social on the wonder of drug repurposing in the RECOVERY trial:

0211

Tune in to hear about: Immortal time bias, confounding by selection, regression discontinuities, platform trials, the uncanny mountain of p-values, high-throughput screening, patent and exclusivity laws, push vs pull funding, indication-based pricing, Focused Research Organisations, and more!

Saloni

New episode of HARD DRUGS! GLP1 drugs have transformed obesity & diabetes, help treat heart disease, kidney disease and sleep apnea. They're far from the only drug with multiple uses. But sometimes, it takes several decades - and public funding - to learn about new uses.

1164
Saloni

New episode of HARD DRUGS! GLP1 drugs have transformed obesity & diabetes, help treat heart disease, kidney disease and sleep apnea. They're far from the only drug with multiple uses. But sometimes, it takes several decades - and public funding - to learn about new uses.

0183

New episode of HARD DRUGS! GLP1 drugs have transformed obesity & diabetes, help treat heart disease, kidney disease and sleep apnea. They're far from the only drug with multiple uses. But sometimes, it takes several decades - and public funding - to learn about new uses.

Are miracle drugs hiding in plain sight?Hard Drugs · Episodeopen.spotify.com
15614

Kalshi recently opened prediction betting markets for clinical trials and drug approvals. It's intriguing, but in my view also risks weakening the integrity of trials and worsening participant dropouts. Short post by me:

Ask your bookie if this drug is right for youWhat we're reading spotlightopen.substack.com
23811
Показать ещё